Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175661 | 0.85 | RIPK1 (0.49) | HCAR3APAF1NPC1RAB9AF10 | |
| SCHEMBL6277706 | 0.85 | RIPK1 (0.49) | HCAR3APAF1NPC1RAB9AF10 | |
| SCHEMBL6285546 | 0.84 | F10 (0.42) | FGFR1HCAR3APAF1NPC1RAB9A | |
| SCHEMBL6112712 | 0.82 | NPC1 (0.62) | FGFR1HCAR3NPC1RAB9AF10 | |
| SCHEMBL6112850 | 0.80 | HPGD (0.57) | FGFR1HCAR3NPC1RAB9AHTT | |
| SCHEMBL9680193 | 0.79 | FGFR1 (0.53) | FGFR1HCAR3NPC1RAB9AF10 | |
| SCHEMBL6285544 | 0.79 | ALDH1A1 (0.51) | HPGDPOLBLMNAALDH1A1MEN1 | |
| SCHEMBL20985903 | 0.78 | MAPT (0.60) | FGFR1APAF1F10HTTSMN1; SMN2 | |
| SCHEMBL6285122 | 0.78 | POLB (0.45) | APAF1NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL6283673 | 0.78 | POLB (0.45) | APAF1HTTSMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | FGFR1 900/4885HCAR3 3590/4885APAF1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.